Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

BACKGROUND: Secukinumab has demonstrated sustained long‐term efficacy with a favourable safety profile in various psoriatic disease manifestations in adults. OBJECTIVES: Here, the efficacy and safety of two secukinumab dosing regimens [low dose (LD) and high dose (HD)] in paediatric patients with se...

Descripción completa

Detalles Bibliográficos
Autores principales: Bodemer, C., Kaszuba, A., Kingo, K., Tsianakas, A., Morita, A., Rivas, E., Papanastasiou, P., Keefe, D., Patekar, M., Charef, P., Zhang, L., Cafoncelli, S., Papavassilis, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986088/
https://www.ncbi.nlm.nih.gov/pubmed/33068444
http://dx.doi.org/10.1111/jdv.17002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986088/
https://www.ncbi.nlm.nih.gov/pubmed/33068444
http://dx.doi.org/10.1111/jdv.17002

Ejemplares similares